Archives: Speakers

Joachim Lövin has worked in the pharmaceutical industry for over 20 years across various therapeutic areas and organizations. During this time, Joachim has worked in different roles spanning over Data Management, Project Management, Process Development, Senior Business Analyst and Clinical Operations. In his current role as DCT Specialist, Joachim focuses on supporting trials including competence development of Clinical Operations, identifying opportunities, and operationalising Decentralised Clinical Trial Elements across Novo Nordisk. Joachim is the Workstream Lead for the Modernizing Clinical Trial Conduct workstream for TransCelerate Biopharma, and a member of the eClinical Forums Trial of the Future. All of Joachim’s work is aligned with his passion to improve patient experience and accelerating clinical trials.

Global pharmaceutical, OMP and pediatric EU legislation. Rare diseases policies . Gene Therapy-ATMP . HTA and access frameworks. Cross border access. Patient engagement. Incentives for medicine development. Repurposing.
– All aspects of medical affairs across the product life cycle – Compassionate Use and Medical Need programs. Diagnostics. Real world evidence and registries
– Multistakeholder engagement

I’m a generalist in a highly specialised environment and a Medical Doctor with over 25 years experience primarily in biotechnology and innovative pharmaceutical companies.

Strong international experience in medical and policy departments collaborate across functions and across stakeholders.

Experienced Patient Advocate active as a volunteer in the non-profit sector in Europe focused on rare diseases and especially rare eye disease. Background in finance and business strategy. Healthcare is in crisis and we need to collaborate to make things better – researchers, clinicians, regulators, payers, industry and patients, we all need to play our part. And across borders too – separatist nonsense like Brexit does not make anything better and we have to expend additional scarce resource to try and overcome the problems it creates

Biography

Nick De Donder graduated as a biomedical scientist from the University of Ghent, Belgium in 2007 and has been employed since 2008 by Business & Decision Life Sciences at their headquarters in Brussels. He has been moving from being a Data Integration Specialist to Project Manager to Line Manager for the Data Standards team. Since 2020 he is Head of Data Standards. Nick is a member of the SDS team, an authorized CDISC trainer for CDASH, SDTM and Newcomers and a PHUSE committee member since 2017. In 2019 he joined the E3C and is now co-chairing it. Since June 2021 Nick has been product owner of the CORE application.

Momna Ali, MSc, is an Analyst at GlobalData’s London office with the Neurology and Immunology teams. She is involved in the production of opportunity assessment and forecasting reports as well as competitive landscape analysis reports, for neuroimmunology-related areas. Additionally, Momna previously worked in a clinical research organization (CRO), managing their medical devices and cardio systems portfolio. Prior to that role, she worked as senior immunizations officer with NHS (National Health Service) England. Momna holds a Master’s of Science in Health Management from City University of London, and a Bachelor’s degree in Biomedical Science from Middlesex, University of London.

I’m committed to change the medical practice, to improve it with impact innovation, bringing solutions to improve the patient journey.
My medical background, curiosity and empathy provides me a strong purpose and has facilitated my performance in different roles during more than 16 years.
I enjoy challenges and diversity to drive sustainable results and long term vision in the pharmaceutical industry. Love leading teams and getting the best of everyone.
My key strengths include agility, empathy and commitment.

A data driven, high performing and results orientated Team Leader, with 20+ years of experience in Strategic Planning and Programs Execution and with 15+ years of experience in direct management and development of teams and individuals, with a proven track record for delivering and optimizing clinical studies, leading high-performing teams in global, matrix-based environment across multiple therapeutic areas and compounds.

Expert in data analysis and interpretation, proficient in tools and technologies associated to project execution and recruitment strategies, and confident to work across different stakeholder groups to develop tactical/operational plans aligned with regulatory and commercial objectives.

Passionate about science, project management and people mentoring and improvement, with also a solid expertise in the regulation of clinical studies and data protection, risk assessment and root cause analysis, audits and implementation of CAPAs.

As a physician scientist, Eugenie Suter, MD, PhD, is dedicated to improving life for people with neurologic disorders. Her commitment
to drug development is founded on experience in research (Ph.D. in Neuroscience at Northwestern University; Immunology at Harvard’s Boston Children’s Hospital) as well as clinical medicine (Northwestern University; UCLA). Dr. Suter enjoys fostering innovation by drawing on her own experience and training in business, clinical trials, public policy and linguistics,. Driven by the need she witnesses clinically, she aims to bring new treatment options to individuals living with neurologic and other life-altering disorders through her work in Neuroscience & Rare Diseases as well as the Cardiovascular & Metabolic group at Roche.